Biolexis Therapeutics: Funding, Investors & Team (Sep 2026)
Biolexis Therapeutics is a biotech company founded by two veterans of both small molecule drug development and life science startups. Cancer biologist Dr. David Bearss is an expert in small-molecule drug development and the use of genetic model systems in drug discovery while Dr. Hariprasad Vankayalapati, a medicinal chemist, brings extensive knowledge and experience in identifying and developing lead candidates for drug discovery. Together, these world-renowned scientists have five decades of wet-lab research and therapeutic development and were pioneers in utilizing computational tools in small molecule discovery. A culmination of their work together and individually, Biolexis takes an unparalleled, chemical-biological approach to accelerate drug discovery. Utilizing our proprietary wet-lab data and our empirically developed AI/ML predictive platform, Moleculern™, Biolexis is able to rapidly discovery and development novel clinical candidates for cancers, immune-mediated, neurodegenerative, auto-immune and inflammatory indications. Moleculern™ uses laboratory-generated molecular data to train and test a set of protein structures, processed through deep learning, cutting-edge ML tools, and transformed into accurate structural models by mapping hot-spots, computing ligand properties and building accurate empirical models. Our process produces active, safe, and efficacious novel chemical entities while reducing costs, accelerating the timeline and increasing the probability of success in clinical trials.
Biolexis Therapeutics has raised $1.6M across 1 funding round on record, the most recent an undisclosed round of $1.6M announced in Jun 2026.
That round is below the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Biolexis Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Biolexis Therapeutics Funding Rounds
Biolexis Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Biolexis Therapeutics Funding Compared to Other Health Care Startups
Biolexis Therapeutics' latest round of $1.6M is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Biolexis Therapeutics in Health Care and American Fork
Companies Similar to Biolexis Therapeutics
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
Biolexis Therapeutics Funding FAQs
What does Biolexis Therapeutics do?
Biolexis Therapeutics is a biotech company founded by two veterans of both small molecule drug development and life science startups. Cancer biologist Dr. David Bearss is an expert in small-molecule drug development and the use of genetic model systems in drug discovery while Dr. Hariprasad Vankayalapati, a medicinal chemist, brings extensive knowledge and experience in identifying and developing lead candidates for drug discovery. Together, these world-renowned scientists have five decades of wet-lab research and therapeutic development and were pioneers in utilizing computational tools in small molecule discovery. A culmination of their work together and individually, Biolexis takes an unparalleled, chemical-biological approach to accelerate drug discovery. Utilizing our proprietary wet-lab data and our empirically developed AI/ML predictive platform, Moleculern™, Biolexis is able to rapidly discovery and development novel clinical candidates for cancers, immune-mediated, neurodegenerative, auto-immune and inflammatory indications. Moleculern™ uses laboratory-generated molecular data to train and test a set of protein structures, processed through deep learning, cutting-edge ML tools, and transformed into accurate structural models by mapping hot-spots, computing ligand properties and building accurate empirical models. Our process produces active, safe, and efficacious novel chemical entities while reducing costs, accelerating the timeline and increasing the probability of success in clinical trials.
How much funding has Biolexis Therapeutics raised?
Biolexis Therapeutics has raised $1.6M across 1 round on record. The most recent is an undisclosed round of $1.6M announced in Jun 2026.
When did Biolexis Therapeutics last raise funding?
Biolexis Therapeutics' most recent funding round on record is an undisclosed round of $1.6M, announced in Jun 2026.
Who founded Biolexis Therapeutics?
FundedIQ lists Tyler Hartmann (Founder) at Biolexis Therapeutics.
Where is Biolexis Therapeutics headquartered?
Biolexis Therapeutics is based in American Fork, Utah, United States.
How many employees does Biolexis Therapeutics have?
Biolexis Therapeutics is in the 1-10 employee band.
How does Biolexis Therapeutics' funding compare to other Health Care startups?
Biolexis Therapeutics' latest round of $1.6M is below the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Biolexis Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Biolexis Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.